Japanese drugmaker Daiichi Sankyo’s (TYO:4568) Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the treatment of adults with hormone receptor (HR) positive, HER2 ...

Cisco has patched a denial of service (DoS) vulnerability that lets attackers crash the Border Gateway Protocol (BGP) process on IOS XR routers with a single BGP update message. IOS XR runs on the ...

Cisco has released patches for 10 vulnerabilities in IOS XR, including five denial-of-service (DoS) bugs. Cisco on Wednesday announced patches for 10 vulnerabilities in IOS XR, including five that ...

BERKELEY, CA, USA I March 11, 2025 I Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, today announced it entered into a Research ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

Fourteen years after the devastating earthquake and tsunami led to the Fukushima Daiichi nuclear accident, the site has made tangible progress in lowering radiation levels. Yet, as the Associated ...

On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan Earthquake and the Fukushima Daiichi nuclear disaster. Fourteen years later ...

--(BUSINESS WIRE)--#RNA--Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, today announced it entered into a Research Collaboration and ...

Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

Japan's health ministry said on Friday it agreed to buy 1.4 million doses of Daiichi Sankyo's updated COVID-19 vaccine. The purchase is contingent on approval of the shot formulated for the XBB.1. ...

A health ministry panel of experts on July 31 endorsed the plan for Daiichi Sankyo Co. to begin producing and distributing the vaccine, which creates immunity for the conventional strain of the virus.

Daiichi Sankyo’s antibody-drug conjugate (ADC) platform has already delivered one drug to the market with blockbuster sales forecasts, with a second due to be filed shortly. Now, a third is ...